Orexo AB (publ) (ORXOY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Orexo AB (publ) (ORXOY) trades at $1.77 with AI Score 46/100 (Grade C). Orexo AB (publ) is a Swedish specialty pharmaceutical company focused on developing and commercializing pharmaceuticals and digital therapies, primarily in opioid dependence… Market cap: $62.2M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ORXOY: ORXOY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ORXOY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ORXOY: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Orexo AB (publ) (ORXOY) Healthcare & Pipeline Overview
Orexo AB (publ) develops and commercializes pharmaceutical and digital therapies, focusing on opioid dependence, pain management, and digital mental health solutions. With a portfolio including Zubsolv and digital therapeutics like deprexis, Orexo operates in the US, Europe, and the UK, facing competition in the specialty pharmaceutical sector.
What Is the Investment Thesis for ORXOY?
Orexo's investment thesis hinges on its focus on opioid dependence treatment and digital therapies, addressing significant unmet needs in healthcare. The company's Zubsolv product maintains a presence in the opioid dependence market. Growth catalysts include the potential approval and commercialization of its pipeline products, such as OX124 and OX125, and expansion of its digital therapeutics offerings. Key risks include competition from generic alternatives, regulatory hurdles, and the company's current negative profit margin of -33.6%. The company's success depends on effective commercialization strategies and successful pipeline development.
Based on FMP financials and quantitative analysis
ORXOY Key Highlights
Market capitalization of $62.2M indicates a small-cap company with potential for growth but also higher volatility.
- Negative P/E ratio of -6.35 reflects current unprofitability, requiring investors to focus on future earnings potential.
- Negative profit margin of -33.6% highlights the need for improved operational efficiency and revenue growth.
- Gross margin of -14.4% suggests cost of goods sold exceeds revenue, indicating pricing or production challenges.
- Beta of 0.83 suggests lower volatility compared to the overall market, potentially offering some downside protection.
Who Are ORXOY's Competitors?
ORXOY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AAWH Ascend Wellness Holdings, Inc. | $0.42 | +6.25% | $86.3M | 43 |
| CBWTF Auxly Cannabis Group Inc. | $1.86 | -0.53% | $190M | 54 |
| HLTRF HLS Therapeutics Inc. | $2.78 | +1.83% | $86.9M | 48 |
| IPHYF Innate Pharma S.A. | $1.65 | +0.00% | $155M | 44 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ORXOY's Key Strengths?
Specialized focus on opioid dependence treatment and digital therapies.
- Proprietary formulations and intellectual property protection.
- Established presence in the United States and Europe.
- Pipeline of pharmaceutical products and digital therapies in development.
What Are ORXOY's Weaknesses?
Negative profit margin and reliance on a limited number of products.
- Competition from generic alternatives and established pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Small market capitalization and limited financial resources.
What Could Drive ORXOY Stock Higher?
Potential regulatory approval and commercial launch of OX124 and OX125 for opioid overdose rescue.
- Expansion of digital therapeutics offerings and partnerships with healthcare providers.
- Increased market penetration of Zubsolv in the opioid dependence treatment market.
What Are the Key Risks for ORXOY?
Financial-distress signal — its Altman Z-Score of 0.12 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Generic competition for Zubsolv and Abstral.
- Changes in healthcare regulations and reimbursement policies.
- Clinical trial failures and regulatory setbacks.
- Currency risk due to fluctuations in the exchange rate between SEK and USD.
What Are the Growth Opportunities for ORXOY?
- Expansion of Digital Therapeutics: Orexo has the opportunity to expand its digital therapeutics offerings, such as deprexis, vorvida, and modia, to address the growing demand for accessible mental healthcare solutions. The global digital therapeutics market is projected to reach $9.68 billion by 2027, offering a substantial growth opportunity for Orexo. Successful commercialization and adoption of these therapies could drive significant revenue growth.
- Pipeline Development: Orexo's pipeline of pharmaceutical products, including OX124 and OX125 for opioid overdose rescue, represents a significant growth opportunity. The market for opioid overdose reversal medications is driven by the ongoing opioid crisis. Successful clinical development and regulatory approval of these products could provide Orexo with a competitive advantage and drive revenue growth.
- Geographic Expansion: Orexo can expand its geographic presence beyond the United States, Europe, and the United Kingdom. Emerging markets in Asia and Latin America offer significant growth potential for its pharmaceutical and digital therapy products. Adapting its products and marketing strategies to local market needs could drive revenue growth and increase market share.
- Strategic Partnerships: Orexo can pursue strategic partnerships with other pharmaceutical companies, healthcare providers, and technology companies to expand its reach and accelerate growth. Collaborations could involve co-development of new products, joint marketing initiatives, or distribution agreements. Strategic partnerships can provide Orexo with access to new markets, technologies, and expertise.
- Market Penetration of Zubsolv: Orexo has the opportunity to increase market penetration of Zubsolv in the opioid dependence treatment market. Despite competition from generic alternatives, Zubsolv's unique formulation and patient benefits could drive increased adoption. Targeted marketing campaigns and partnerships with healthcare providers could increase market share and revenue.
What Are ORXOY's Competitive Advantages?
- Proprietary formulations of pharmaceutical products like Zubsolv.
- Intellectual property protection for its digital therapies.
- Established relationships with healthcare providers and payers.
- Expertise in developing and commercializing specialty pharmaceutical products.
What Does ORXOY Do?
Orexo AB (publ) is a Swedish specialty pharmaceutical company founded in 1994 and headquartered in Uppsala. The company focuses on developing and commercializing innovative pharmaceuticals and digital therapies, primarily targeting opioid dependence, pain management, and mental health. Its product portfolio includes Zubsolv, a sublingual tablet for the treatment of opioid dependence, Abstral, used for breakthrough cancer pain, and Edluar, a treatment for short-term insomnia. Orexo is also developing a pipeline of products including OX124 and OX125 for opioid overdose rescue, OX640 for allergic reactions, and OX338 for moderate to severe pain. The company's digital therapies segment includes deprexis for depression, vorvida for alcohol use disorder, and modia for opioid use disorder. Orexo operates in the United States, Europe, and the United Kingdom, marketing its products and therapies to healthcare providers and patients. The company aims to improve patient outcomes and reduce healthcare costs through its innovative solutions.
What Products and Services Does ORXOY Offer?
- Develops and commercializes pharmaceutical products for opioid dependence treatment.
- Offers digital therapies for mental health conditions such as depression and alcohol use disorder.
- Markets Zubsolv, a sublingual tablet for opioid dependence.
- Provides Abstral for the treatment of breakthrough pain in cancer patients.
- Develops medications for opioid overdose rescue, including OX124 and OX125.
- Creates digital therapeutics like deprexis for depression and vorvida for alcohol use disorder.
How Does ORXOY Make Money?
- Develops and commercializes specialty pharmaceutical products.
- Generates revenue through sales of prescription medications like Zubsolv and Abstral.
- Offers digital therapies on a subscription or licensing basis.
- Partners with healthcare providers and payers to distribute its products and therapies.
What Industry Does ORXOY Operate In?
Orexo operates within the specialty pharmaceutical and digital therapeutics industry. The market for opioid dependence treatment is driven by the ongoing opioid crisis and the need for effective therapies. The digital therapeutics market is experiencing rapid growth, driven by increasing adoption of digital health solutions and the need for accessible mental healthcare. Orexo competes with other pharmaceutical companies and digital health providers, including AAWH, BKUH, CBWTF, HLTRF, and IPHYF, in a fragmented and competitive landscape.
Who Are ORXOY's Key Customers?
- Patients suffering from opioid dependence.
- Patients experiencing breakthrough pain due to cancer.
- Individuals seeking treatment for depression and alcohol use disorder.
- Healthcare providers prescribing medications and recommending digital therapies.
- Hospitals and clinics offering addiction treatment and mental health services.
Orexo AB (publ) Financial Trajectory
Orexo AB (publ) (ORXOY) reported $3.5M in revenue for Q2 2026, a decline of 30.0% compared to the prior quarter. The company recorded a net loss of $100.4M, with diluted EPS of $-2.80. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ORXOY averaged $-1.98 in diluted EPS.
Company Profile
Orexo AB (publ) operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Uppsala, SE. The company is led by CEO Nikolaj Sørensen. ORXOY has traded publicly since 2018.
How Orexo AB (publ) Is Valued
Orexo AB (publ) carries a market capitalization of $62.2M, placing it in the micro-cap category. Relative to its peer group, ORXOY's quantitative score of 46/100 is roughly in line with the peer average of 51/100.
Key Financial Metrics
Return on assets is -40.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 18.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Orexo AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.12 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Orexo AB (publ) has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 110.4% below estimates on average.
Forward Outlook
Wall Street analysts project Orexo AB (publ) revenue of about $19.2M for fiscal 2026, with EPS near $-9.88.
ORXOY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on opioid dependence treatment and digital therapies.
- Proprietary formulations and intellectual property protection.
- Established presence in the United States and Europe.
- Pipeline of pharmaceutical products and digital therapies in development.
Bear Case
- Negative profit margin and reliance on a limited number of products.
- Competition from generic alternatives and established pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Small market capitalization and limited financial resources.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $4M | -$100M | -$2.80 |
| Q1 2026 | $5M | -$134M | -$3.00 |
| Q4 2025 | $3M | -$44M | -$1.27 |
| Q3 2025 | $118M | -$30M | -$0.85 |
Based on FMP financials and quantitative analysis
ORXOY Latest News
No recent news available for ORXOY.
ORXOY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ORXOY.
Price Targets
Wall Street price target analysis for ORXOY.
ORXOY MoonshotScore
What does this score mean?
The MoonshotScore rates ORXOY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Nikolaj Sorensen
CEO
Nikolaj Sorensen serves as the CEO of Orexo AB (publ). His background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and strategic development. He has held leadership positions in various pharmaceutical companies, contributing to the launch and growth of several key products. Sorensen's expertise spans across multiple therapeutic areas, including addiction treatment and mental health.
Track Record: Under Nikolaj Sorensen's leadership, Orexo has focused on expanding its digital therapeutics portfolio and advancing its pipeline of pharmaceutical products. Key milestones include the continued commercialization of Zubsolv and the development of new medications for opioid overdose rescue. Sorensen has also emphasized strategic partnerships to expand Orexo's reach and accelerate growth.
Orexo AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. ORXOY is a Level 1 ADR, meaning it trades over-the-counter (OTC) rather than on a major exchange. This allows U.S. investors to invest in Orexo AB (publ) without directly dealing with foreign markets.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ORXO
ORXOY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Orexo AB (publ) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial reporting and transparency.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Increased price volatility.
- Potential for fraud or manipulation.
- Review the company's website and investor relations materials.
- Search for news articles and press releases about the company.
- Check the company's filings with regulatory agencies in Sweden.
- Assess the company's financial performance and condition.
- Evaluate the company's management team and corporate governance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Established business operations in Sweden.
- Development and commercialization of pharmaceutical products and digital therapies.
- Presence in the United States, Europe, and the United Kingdom.
- Management team with experience in the pharmaceutical industry.
- Listing on the Nasdaq Stockholm exchange (ORXO).
Orexo AB (publ) Healthcare Stock: Key Questions Answered
What does the AI Score mean for ORXOY?
ORXOY holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Orexo AB (publ) is a Swedish specialty pharmaceutical company focused on developing and commercializing pharmaceuticals and digital therapies, primarily in opioid dependence and pain management …
What does Orexo AB (publ) do?
Orexo AB (publ) is a specialty pharmaceutical company that develops and commercializes pharmaceutical and digital therapies, primarily focusing on opioid dependence, pain management, and digital mental health. Its key product is Zubsolv, a sublingual tablet for opioid dependence treatment. Additionally, Orexo offers digital therapies like deprexis for depression and vorvida for alcohol use disorder.
What do analysts say about ORXOY stock?
Analyst coverage of ORXOY stock is limited due to its OTC listing and small market capitalization. However, analysts generally focus on Orexo's potential for growth in the opioid dependence treatment market and the digital therapeutics space. Key valuation metrics include revenue growth, profitability, and pipeline development.
What are the main risks for ORXOY?
The main risks for Orexo AB (publ) include generic competition for its pharmaceutical products, regulatory hurdles and clinical trial risks, and the company's current negative profit margin. As an OTC-listed stock, ORXOY also faces risks related to limited liquidity, increased price volatility, and potential for fraud or manipulation.
What are the key factors to evaluate for ORXOY?
Orexo AB (publ) (ORXOY) holds an AI score of 46/100 (low). Orexo's investment thesis hinges on its focus on opioid dependence treatment and digital therapies, addressing significant unmet needs in healthcare. Not financial advice.
How frequently does ORXOY data refresh on this page?
ORXOY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ORXOY's recent stock price performance?
Orexo AB (publ) (ORXOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on opioid dependence treatment and digital therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORXOY overvalued or undervalued right now?
Orexo AB (publ) (ORXOY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ORXOY before investing?
Before investing in Orexo AB (publ) (ORXOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for ORXOY due to its OTC listing.
- Financial data based on available information and may not be comprehensive.